Neurodegenerative disorders are characterized by the progressive accumulation of misfolded protein aggregates that eventually lead to the loss of selected neuronal populations. Immunotherapy has been shown in the recent years as a promising approach for targeting, clearing, and reducing the accumulation of protein aggregates. Alzheimer's disease (AD), which is the most common neurodegenerative disorder, has been the focus of numerous immunotherapeutic studies because the extracellular nature of the amyloid-β (Aβ) peptide. The aim of the current work is to dissect the state-of-the-art of anti-Aβ immunotherapy for AD. The rationale behind anti-Aβ antibodies, what has happened in clinical trials, and which strategies have been designed to avoid side-effects and improve the efficacy of those antibodies are presented.

神经退行性疾病的特征在于错误折叠的蛋白质聚集体的逐步积累，最终导致所选神经元群体的丢失。近年来，免疫疗法已被证明是靶向，清除和减少蛋白质聚集体积累的一种有前途的方法。阿尔茨海默氏病（AD）是最常见的神经退行性疾病，由于淀粉样β（Aβ）肽的胞外特性，已成为众多免疫治疗研究的重点。当前工作的目的是剖析AD抗Aβ免疫疗法的最新技术。介绍了抗Aβ抗体的基本原理，临床试验中发生的情况以及设计出的避免副作用和提高这些抗体功效的策略。